Other Mutations: MAPK

NCT04418167: JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

NCT04418167
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MAPK, MEK, RAS, RAF
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have a histologically or cytologically confirmed MAPK pathway mutation to be eligible, Breast cancer patients are only eligible for the dose escalation phase (not the expansion phase)
Exclusions: Patients with symptomatic central nervous system metastasis
https://ClinicalTrials.gov/show/NCT04418167

NCT04185831: A Molecularly Guided Anti-Cancer Drug Off-Label Trial

NCT04185831
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NF1/2, MAPK, mTOR, TSC, TMB-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active progressive CNS metastases – see trial for details
https://ClinicalTrials.gov/show/NCT04185831

Up ↑